A clinical-stage biotechnology company developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company is focused on advancing verekitug, a therapeutic candidate in Phase 2 trials for conditions including severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.